ARAVIVE (ARAV)
(Delayed Data from NSDQ)
$0.04 USD
0.00 (0.00%)
Updated Jan 26, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
ARAVIVE, INC [ARAV]
Reports for Purchase
Showing records 61 - 80 ( 104 total )
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
CORRECTED: ASCO Virtual Meeting Abstract Roundup
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
COVID-19 Impact on Coverage Universe: Week of April 27 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Looking Toward the Future for New Assets; Important AVB-500 Update This Summer
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
COVID-19 Impact on Coverage Universe: Week of April 20 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
COVID-19 Impact on Coverage Universe: Week of April 13 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Management and Board Transition Strengthens Aravive''s Position; Important Upcoming Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
Company: ARAVIVE, INC
Industry: Medical - Generic Drugs
AVB-500 Begins IST in Urothelial Carcinoma; Key Catalysts In Ovarian Cancer Approach
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J